Research & Development
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human U...
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hu...
genedrive partners with Thermo Fisher Scientific to develop high-throughput CYP2C19 test
29 June 2026 - Pharmacogenetic testing company genedrive plc (AIM: GDR) disclosed on Monday that it has entered a collaboration agreement with Thermo Fisher Scientific Inc (NYSE: TMO) to develop the G...
Sobi receives US FDA's complete response letter for NASP (nanoencapsulated sirolimus plus pegadricase)
29 June 2026 - Sobi (STO: SOBI), a Sweden-based biopharmaceutical company, announced on Friday that the company received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA)...
Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma
29 June 2026 - Anivive Lifesciences, a California-based pharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) Center for Veterinary Medicine has granted full appro...
Lupin's Enzalutamide Tablets receive for tentative US FDA approval
29 June 2026 - India-based global pharmaceutical company Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced on Friday that it has received tentative appr...